Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS) - Poddubnyy, D; Hermann, K G; Callhoff, J (Ann Rheum Dis, 2014)
et al.